Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial

著者: Laurie H. Sehn, Neil Chua, Jiřı́ Mayer, Gregg Dueck, Marek Trněný, Kamal Bouabdallah, Nathan Fowler, Vincent Delwail, Oliver W. Press, Gilles Salles, John G. Gribben, Anne Lennard, Pieternella J. Lugtenburg, Natalie Dimier, Elisabeth Wassner-Fritsch, Günter Fingerle‐Rowson, Bruce D. Cheson - The Lancet 2016 被引用: 343